The past decade of multiple sclerosis research has been marked by important advances in understanding the disease, a dramatic increase in the range of treatment options and a new spirit of data sharing in research for patient benefit. This progress has made personalized medicine in multiple sclerosis a realistic possibility.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hauser, S. L. et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).
Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).
International Multiple Sclerosis Genetics Consortium et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473–477 (2005).
Tobin, W. O., Weinshenker, B. G. & Lucchinetti, C. F. Longitudinally extensive transverse myelitis. Curr. Opin. Neurol. 27, 279–289 (2014).
Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).
Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213–2221 (2014).
Multiple Sclerosis Discovery Forum [online] (2015).
Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).
Palace, J. et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 14, 497–505 (2015).
Acknowledgements
The author gratefully acknowledges personal support from the Edmond Safra Foundation and Lily Safra, the Imperial College Healthcare Trust Biomedical Research Centre, and as an NIHR Senior Investigator.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received funding for his research from GlaxoSmithKline and Biogen. The author has received speaker's fees or honoraria paid to his institution from Adelphi Communications, Biogen, IXICO, GlaxoSmithKline and Novartis.
Rights and permissions
About this article
Cite this article
Matthews, P. New drugs and personalized medicine for multiple sclerosis. Nat Rev Neurol 11, 614–616 (2015). https://doi.org/10.1038/nrneurol.2015.200
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.200
This article is cited by
-
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Nature Reviews Neurology (2019)
-
The characterization of decellularized human skeletal muscle as a blueprint for mimetic scaffolds
Journal of Materials Science: Materials in Medicine (2016)